Oxford Nanopore Technologies Ltd Total Assets
Oxford Nanopore Technologies Ltd total assets. Based on the latest financial reports, Oxford Nanopore Technologies Ltd (ONT) holds total assets worth GBX565.40 Million GBX (≈ $68.79K USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Oxford Nanopore Technologies Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Oxford Nanopore Technologies Ltd (2012–2025)
Total assets of Oxford Nanopore Technologies Ltd from 2012 to 2025. This chart illustrates how Oxford Nanopore Technologies Ltd's total assets have evolved over time, based on quarterly financial data. See latest Oxford Nanopore Technologies Ltd stock price today for real-time trading data and today's change.
Oxford Nanopore Technologies Ltd - Asset Composition Analysis
Oxford Nanopore Technologies Ltd Total Assets Breakdown (December 2025)
Oxford Nanopore Technologies Ltd total assets breakdown as of December 2025. Oxford Nanopore Technologies Ltd's total assets of GBX565.40 Million consist of 67.5% current assets and 32.5% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 29.1% |
| Accounts Receivable | GBX52.50 Million | 8.4% |
| Inventory | GBX81.50 Million | 13.1% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX55.80 Million | 9.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Oxford Nanopore Technologies Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ONT working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oxford Nanopore Technologies Ltd's current assets represent 67.5% of total assets in 2025, a decrease from 97.0% in 2012.
- Cash Position: Cash and equivalents constituted 29.1% of total assets in 2025, down from 42.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 13.1% of total assets.
Oxford Nanopore Technologies Ltd Competitors by Total Assets
Key competitors of Oxford Nanopore Technologies Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Oxford Nanopore Technologies Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.52 | 4.79 | 6.76 |
| Quick Ratio | 2.73 | 3.89 | 5.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX256.20 Million | GBX401.60 Million | GBX301.34 Million |
Oxford Nanopore Technologies Ltd - Advanced Valuation Insights
This section examines the relationship between Oxford Nanopore Technologies Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.63 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -16.1% |
| Total Assets | GBX622.50 Million |
| Market Capitalization | $24.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oxford Nanopore Technologies Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oxford Nanopore Technologies Ltd's assets decreased by 16.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oxford Nanopore Technologies Ltd (2012–2025)
The table below shows the annual total assets of Oxford Nanopore Technologies Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX622.50 Million ≈ $75.74K |
-16.11% |
| 2024-12-31 | GBX742.05 Million ≈ $90.29K |
-4.51% |
| 2023-12-31 | GBX777.06 Million ≈ $94.55K |
-5.68% |
| 2022-12-31 | GBX823.89 Million ≈ $100.24K |
-2.14% |
| 2021-12-31 | GBX841.87 Million ≈ $102.43K |
+199.37% |
| 2020-12-31 | GBX281.21 Million ≈ $34.22K |
+70.70% |
| 2019-12-31 | GBX164.74 Million ≈ $20.04K |
-5.97% |
| 2018-12-31 | GBX175.19 Million ≈ $21.32K |
+46.84% |
| 2017-12-31 | GBX119.31 Million ≈ $14.52K |
-24.94% |
| 2016-12-31 | GBX158.94 Million ≈ $19.34K |
+46.13% |
| 2015-12-31 | GBX108.77 Million ≈ $13.23K |
+54.72% |
| 2014-12-31 | GBX70.30 Million ≈ $8.55K |
+2.08% |
| 2013-12-31 | GBX68.87 Million ≈ $8.38K |
+32.58% |
| 2012-12-31 | GBX51.95 Million ≈ $6.32K |
-- |
About Oxford Nanopore Technologies Ltd
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version… Read more